Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of iGlarLixi Compared to IDegAsp in Type 2 Diabetes Mellitus
CTR20221042Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started May 2022; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20221042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221042.